Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia
Experimental Hematology · 2024
DOI: 10.1016/j.exphem.2024.104670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Hematology, 2024. Verfasst von Jianping Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Anemia, Aplastic, Immunosuppressive Agents, Pyrazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disease. The addition of eltrombopag to immunosuppressive therapy (IST) improves the response rate, but its hepatotoxicity is concerning. Avatrombopag (AVA), a small-molecule thrombopoietin-receptor agonist without hepatotoxicity, has unknown efficacy in SAA treatment. This retrospective study assessed the efficacy and safety of AVA added to IST 42 SAA patients compared to a historical cohort of 84 patients receiving IST alone, using propensity score matching. The median age was 31.5 (6.0-67.0 years) years old in group A and 26 (16.0-45.0 years) years old in group B. At 3 months, group A showed higher complete response (CR) and overall response (OR) rates than group B (CR: 19.0% vs. 4.8%, p = 0.024; OR: 54.8% vs. 39.3%, p = 0.145). Higher CR and OR rates were also found at 6 months in group A than in group B (CR: 31.0% vs. 14.3%, p = 0.145; OR 71.4% vs. 51.2%, p = 0.048). In multivariate analysis of group A, a shorter interval from disease onset to antithymocyte globulin (ATG) treatment (≤6 months) (p = 0.005) predicted better responses rate at 6 months. Event-free survival was also improved in group A (60.7% vs. 49.6%). AVA was well-tolerated, with no hepatic injury observed during treatment, even in those with pre-existing hepatic impairment. The addition of AVA to IST improves both the response rate and response quality in patients with SAA while ensuring safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
Zitieren
APA
Li, J., Liang, W., Fan, H., Zhou, K., Li, Y., Yang, W., Jing, L., Zhang, L., Ye, L., Xiong, Y., Peng, G., Yang, Y., Yuan, W., Shi, J., Zhang, F., & Zhao, X. (2024). Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia. Experimental Hematology. https://doi.org/10.1016/j.exphem.2024.104670
Vancouver
Li J, Liang W, Fan H, Zhou K, Li Y, Yang W, et al. Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia. Experimental Hematology. 2024. doi:10.1016/j.exphem.2024.104670
BibTeX
@article{Li2024,
author = {Li, Jianping and Liang, Weiru and Fan, Huihui and Zhou, Kang and Li, Yuan and Yang, Wenrui and Jing, Liping and Zhang, Li and Ye, Lei and Xiong, Youzhen and Peng, Guangxin and Yang, Yang and Yuan, Weiping and Shi, Jun and Zhang, Fengkui and Zhao, Xin},
title = {Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia},
journal = {Experimental Hematology},
year = {2024},
doi = {10.1016/j.exphem.2024.104670}
}
EUVIMED